Graffinity Pharmaceuticals GmbH was founded as Graffinity Pharmaceutical Design GmbH and later became Graffinity Pharmaceuticals AG. The company is involved in the lead discovery and development of small molecule pharmaceuticals. Graffinity’s mission is to combine fragment-based drug discovery with low-affinity fragment screening, serve its partners in providing high-quality lead structures, and become a leading provider of chemobiological information and NCEs.